[go: up one dir, main page]

AR104174A1 - Oxadiazoles sustituidos con deuterio - Google Patents

Oxadiazoles sustituidos con deuterio

Info

Publication number
AR104174A1
AR104174A1 ARP160100894A ARP160100894A AR104174A1 AR 104174 A1 AR104174 A1 AR 104174A1 AR P160100894 A ARP160100894 A AR P160100894A AR P160100894 A ARP160100894 A AR P160100894A AR 104174 A1 AR104174 A1 AR 104174A1
Authority
AR
Argentina
Prior art keywords
oxadiazols
deuterio
replaced
deuterium
deuterated
Prior art date
Application number
ARP160100894A
Other languages
English (en)
Inventor
Chakma Justin
Zhang Chengzhi
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of AR104174A1 publication Critical patent/AR104174A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen moduladores deuterados de los receptores S1P1 de fórmula (1), sus composiciones farmacéuticas y sus procedimientos de uso, en donde R¹ - R²⁴ se seleccionan de modo independiente del grupo que consiste en hidrógeno y deuterio y al menos uno de R¹ - R²⁴ es deuterio o contiene deuterio.
ARP160100894A 2015-04-06 2016-04-01 Oxadiazoles sustituidos con deuterio AR104174A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562143489P 2015-04-06 2015-04-06

Publications (1)

Publication Number Publication Date
AR104174A1 true AR104174A1 (es) 2017-07-05

Family

ID=55697512

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100894A AR104174A1 (es) 2015-04-06 2016-04-01 Oxadiazoles sustituidos con deuterio

Country Status (8)

Country Link
US (1) US20180016244A1 (es)
EP (1) EP3280703A1 (es)
AR (1) AR104174A1 (es)
AU (1) AU2016246398A1 (es)
CA (1) CA2981743A1 (es)
IL (1) IL254679A0 (es)
TW (1) TW201636336A (es)
WO (1) WO2016164180A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017180794A1 (en) 2016-04-13 2017-10-19 Skyline Antiinfectives, Inc. Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
US11111223B2 (en) * 2016-06-14 2021-09-07 Receptos Llc Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
EP3502100A1 (en) 2016-08-19 2019-06-26 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of ozanimod and preparation method therefor
CN109640982A (zh) 2016-09-14 2019-04-16 苏州科睿思制药有限公司 奥扎莫德盐酸盐的晶型及其制备方法
CN106674053A (zh) * 2016-12-27 2017-05-17 苏州山青竹生物医药有限公司 一种3‑氰基‑4‑异丙氧基苯甲酸甲酯的制备方法
CN108727292A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 一种奥扎莫德及其中间体的制备方法
CN108727291A (zh) * 2017-04-21 2018-11-02 宁波爱诺医药科技有限公司 奥扎莫德及其中间体的制备方法
EP3677575A4 (en) 2017-08-31 2020-07-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTALLINE FORM OF OZANIMODHYDROCHLORIDE AND PRODUCTION METHOD THEREFOR
WO2019058290A1 (en) * 2017-09-20 2019-03-28 Suven Life Sciences Limited IMPROVED PROCESS FOR THE PREPARATION OF AZANIMOD A-AMINO COMPOUND
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CN110615747A (zh) * 2018-06-20 2019-12-27 广东东阳光药业有限公司 一种二氢茚中间体的制备方法
US20220144788A1 (en) * 2019-03-29 2022-05-12 Receptos Llc Sphingosine 1 phosphate receptor modulators
WO2020205481A1 (en) * 2019-03-29 2020-10-08 Celgene International Ii Sarl Sphingosine 1 phosphate receptor modulators
CN113939507A (zh) * 2019-03-29 2022-01-14 瑞塞普托斯公司 1-磷酸鞘氨醇受体调节剂
JP2022529845A (ja) * 2019-04-26 2022-06-24 レセプトス・リミテッド・ライアビリティ・カンパニー スフィンゴシン１リン酸受容体調節因子
CN110256288A (zh) * 2019-05-13 2019-09-20 苏州山青竹生物医药有限公司 一种制备(s)-1-氨基-2,3-二氢-1h-茚-4-甲腈的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2291080B1 (en) 2008-05-14 2015-08-19 The Scripps Research Institute Novel modulators of sphingosine phosphate receptors
US8446183B2 (en) 2009-06-25 2013-05-21 Nova Research, Inc. High current emitter drive unit cell
PT3406142T (pt) 2009-11-13 2021-03-26 Receptos Llc Moduladores seletivos de recetor de esfingosina 1 fosfato e métodos de síntese quiral

Also Published As

Publication number Publication date
EP3280703A1 (en) 2018-02-14
AU2016246398A1 (en) 2017-10-26
TW201636336A (zh) 2016-10-16
IL254679A0 (en) 2017-11-30
WO2016164180A1 (en) 2016-10-13
CA2981743A1 (en) 2016-10-13
US20180016244A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
AR104174A1 (es) Oxadiazoles sustituidos con deuterio
CL2018001478A1 (es) Agonistas del receptor de apelina y métodos de uso
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
CO2019003178A2 (es) Compuestos de dinucleótidos cíclicos
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CL2016002348A1 (es) Agonistas del receptor muscarínico
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CO2017012995A2 (es) Derivados análogos de heteroarilos/arilo actvos como reguladores nrf2 y composiciones farmacéuticas de los mismos
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
CR20170384A (es) Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
CR20150436A (es) Nuevos octahidro-pirrolo[3,4-c]-pirrol y -piridina-fenilo
PE20180483A1 (es) Oxiesteroles y metodos de uso de los mismos
UY37169A (es) Análogos de 1,4-dihidropirimidin-5-carboxamidas como agonistas de apj y composiciones que los contienen
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
CR20190268A (es) Nuevos deribados de isoxazolil éter como pam de gaba a alfa5
BR112017011387A2 (pt) uso de compostos, e, composição cosmética.
CL2020000101A1 (es) Compuestos de cetonas bicíclicas y métodos de uso de los mismos.
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal

Legal Events

Date Code Title Description
FB Suspension of granting procedure